CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Herb Cross

Profile

Herb Cross

Chief Financial Officer (Principal Accounting and Financial Officer), Jasper Therapeutics, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Jasper Therapeutics, Inc. named Jeet Mahal to succeed Herb Cross on an interim basis, effective October 9, 2026.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Jasper Therapeutics, Inc. (JSPR)
Biological Products, (No Diagnostic Substances)
Chief Financial Officer (Principal Accounting and Financial Officer)Former2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. October 9, 2026effective

    Jasper Therapeutics, Inc. named Jeet Mahal to succeed Herb Cross on an interim basis, effective October 9, 2026. Profile of Jeet Mahal.

    On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the “ Company ”) in order […]

    [2] Filing by Jasper Therapeutics, Inc., filed with the SEC on September 28, 2026. Read the filing. The record at CFO Tribune.

  2. March 30, 202610-K filed

    Herb Cross signed the annual report of Jasper Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Accounting and Financial Officer), filed March 30, 2026.

    /s/ Herb Cross Chief Financial Officer March 30, 2026 Herb Cross (Principal Accounting and Financial Officer)

    [1] Annual report on Form 10-K by Jasper Therapeutics, Inc., filed with the SEC on March 30, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Jasper Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 30, 2026. sec.gov; record.
  2. Current report filed with the SEC, Jasper Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 28, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Herb Cross wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.